Clinical-stage biotech is one of the few corners of the market where a sub-$30 share price genuinely matters: small-cap oncology names can re-rate violently around a single Phase 3 readout or FDA decision, and 2026 is stacked with catalysts. For retail investors scanning headlines, the question is rarely about valuation multiples (most of these companies are pre-revenue) and almost always about pipeline quality, cash runway, and Wall Street conviction.
With that in mind, here are three well-rated biotechs trading under $30 where the fundamentals (cash on hand, analyst support, and near-term clinical milestones) line up behind the bull case.
Relay Therapeutics (NASDAQ: RLAY)
Relay Therapeutics (NASDAQ:RLAY) is a clinical-stage precision drug company using its Dynamo platform to design protein-motion-based oncology drugs, led by PI3Kα inhibitor zovegalisib.
Shares continue to trade well inside the $30 ceiling, and the stock is up 50.35% year to date and 286.63% over the past year. Q4 2025 was a clear beat: EPS of -$0.32 versus -$0.40 consensus and revenue of $7.00 million versus $4.34 million expected, with the net loss narrowing to $54.89 million from $76.00 million. The balance sheet shows $554.52 million in cash and investments, supporting runway into 2029.
The bull case is straightforward: 12 buy ratings, zero holds, an analyst target of $21 implying 65.09% upside, and an FDA Breakthrough Therapy designation for zovegalisib heading into Phase 1/2 data at ESMO TAT on March 16, 2026. CEO Sanjiv Patel framed it directly: “In 2026, Relay is entering a pivotal period defined by multiple upcoming clinical milestones across our zovegalisib program.” The risk: cash declined from $781 million to $555 million year over year, and trial outcomes are never guaranteed. The setup still favors patient holders.
Erasca (NASDAQ: ERAS)
Erasca (NASDAQ:ERAS) is a precision oncology biotech going after the RAS/MAPK pathway with pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001.
The stock trades near $10 after a sharp 53.33% one-week pullback to begin May, though it remains up 169.62% YTD and 573.15% over one year. Erasca holds $362.38 million in cash with runway into 2H 2028, and trimmed Q3 R&D to $22.47 million from $27.63 million. Analyst conviction is firm: 8 of 10 analysts rate it Buy or Strong Buy, with a target of $20.70 implying 106.38% upside.
The bull case rests on two Phase 1 monotherapy readouts in 2026 and IP protection on ERAS-0015 through September 2043. CEO Jonathan Lim said clinical development is “on track, with initial Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026.” Risk: it’s pre-revenue, RAS/MAPK has humbled larger players, and recent volatility shows how fragile sentiment is. Even so, the cash cushion and analyst alignment justify the look.
Summit Therapeutics (NASDAQ: SMMT)
Summit Therapeutics (NASDAQ:SMMT | SMMT Price Prediction) is developing ivonescimab, a PD-1/VEGF bispecific antibody licensed from Akeso, across NSCLC, CRC, and HNSCC indications.
Shares finished at $16.11 on May 1 after a brutal 24.91% single-day drop, leaving the largest of the three with a market cap of $12.51 billion. Q1 2026 non-GAAP EPS came in at -$0.15 versus -$0.196 expected, and the company holds $598.70 million in cash and short-term investments with no debt. Analyst support is heavy: 12 buys and 4 holds, with a $31.10 target implying 92.99% upside.
The catalyst calendar is what makes Summit interesting: HARMONi-6 overall survival data at the ASCO Plenary on May 31, 2026, followed by an FDA PDUFA date of November 14, 2026 for ivonescimab in EGFR-mutated NSCLC. The bear flag is real: analysts have flagged runway concerns given $122.3 million in Q1 2026 operating outflows, and HARMONi-3 squamous interim PFS did not reach statistical significance. Yet with imminent regulatory and clinical readouts, the risk/reward stays compelling.
The Bottom Line
A share price under $30 is just a screening filter. Clinical-stage biotech is binary by nature: catalysts can double a name or cut it in half overnight. RLAY, ERAS, and SMMT screen well on cash runway, analyst conviction, and 2026 milestone density, but readers should size positions accordingly and do their own diligence before stepping in.
Top Gaining Stocks
Top Losing Stocks